FCF Biotech
Venture Capital Monitor
-
USA

The FCF Biotech Venture Capital Monitor – USA is a monthly published overview of venture capital trends in the US-Biotech sector.

FCF Biotech Venture Capital Monitor - USA

As of the end of April 2022, we identify the following current VC trends in the US-Biotech sector:

  • In 2022, overall Biotech funding in the USA has reached USD 12,289m so far
  • Top 5 deals exceed USD 190m each, largest transaction amounted to USD 3,000m in Altos Labs
  • Catalio Capital Management (USA) leads the Top 5 Investors (by deal volume), followed by RA Capital Management (USA) and OrbiMed (USA)
  • Central Nervous System dominates as the top indication
    •  

Capital Markets Research

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:

NEWS